Search
diatrizoate
Indications:
1) cerebral angiography
2) urography
- cystourethrography
3) aortography
4) arteriography
5) splenoportography
6) examination of the GI tract (powder)
7) computerized tomography [3]
8) intravenous pyelography
9) cholangiography
10) hysterosalpingography
11) venography [3]
Contraindications:
1) hypersensitivity to diatrizoate or any of its components
2) allergy to shellfish requires premedication (see contrast agent)
Adverse effects:
- not common (1-10%)
1) cardiac:
- hypertension, hypotension, tachycardia, bradycardia, palpitations, chest pain, ventricular arrhythmias, cardiac arrest, pulmonary edema
2) vascular:
- venospasm, venous pain, thrombophlebitis, tissue necrosis at injection site,
3) respiratory:
- rhinitis, sneezing, shortness of breath, coughing, wheezing, laryngospasm, bronchospasm, laryngeal edema, nasal congestion
4) skin:
- urticaria, pruritus, rash, cellulitis, erythema,
5) nervous system
- seizures, dizziness, headache, pain, tremor,
6) nausea/vomiting,
7) acute renal failure
- oliguria, transient proteinuria
8) sensation of warmth
Mechanism of action:
1) Oral contrast agent
2) IV contrast agent: ionic, high osmolality
3) contains organically bound iodine (290-370 mg/mL)
Interactions
drug adverse effects of contrast agents
Specific
diatrizoate sodium (Hypaque)
General
contrast agent
salt
Properties
Database Correlations
PUBCHEM correlations
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Deprecated Reference
Component-of
diatrizoate meglumine (Angiovist, Cystografin, Reno-M-60, Reno-M-Dip, Hypaque-Cysto, Hypaque Meglumine, Urovist Cysto, MD-76R, ME-Gastroview)
diatrizoate meglumine/diatrizoate sodium (Gastrografin, Gastrovist, Renografin)
diatrizoate meglumine/iodipamide (Sinografin)